Amgen Inc. on Thursday reported a net loss of $48.4 million, or$1.13 per share, on revenues of $153.9 million for its 1991first quarter ended June 30.
The loss included a previously announced pre-tax chargeassessed in arbitration proceedings with Johnson & Johnsonover erythropoietin (EPO). Without the charge, officially set at$129 million, net income would have been $40.1 million or 83cents per share. For the comparable quarter of 1990, theThousand Oaks, Calif.-based company had net income of $11.1million, or 29 cents a share, on revenues of $71.7 million.
Revenues for the company's EPO product, Epogen, were $101.5million for the quarter; Neupogen granulocyte colonystimulating factor revenues were $33.4 million.
Amgen stock (NASDAQ:AMGN) closed at $134.75, up $2.75, onThursday.
(c) 1997 American Health Consultants. All rights reserved.